Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
CardioVascular and Interventional Radiology
Published in: CardioVascular and Interventional Radiology 1/2014

01-02-2014 | Clinical Investigation

A Role for Adjuvant RFA in Managing Hepatic Metastases from Gastrointestinal Stromal Tumors (GIST) After Treatment with Targeted Systemic Therapy Using Kinase Inhibitors

Authors: Antoine Hakimé, Axel Le Cesne, Frederic Deschamps, Geoffroy Farouil, Sana Boudabous, Anne Aupérin, Julien Domont, Thierry Debaere

Published in: CardioVascular and Interventional Radiology | Issue 1/2014

Login to get access

Abstract

Purpose

This study was designed to assess the role of radiofrequency ablation (RFA) in the multimodality management of gastrointestinal stromal tumors (GIST) in patients undergoing targeted tyrosine kinase inhibitor therapy (TKI) for liver metastases.

Methods

Outcomes of 17 patients who underwent liver RFA for 27 metastatic GIST after TKI therapy, from January 2004 to March 2012, were retrospectively analyzed. Mean maximum tumor diameter was 2.5 ± 1 cm (range 0.9–4.5 cm). In seven patients (group A), RFA of all residual tumors was performed, with curative intent, and TKI therapy was discontinued. In five patients (group B), RFA of all residual tumors was performed upon achieving the best morphological response with TKI therapy, which was maintained after RFA. In another five patients (group C), RFA was performed on individual liver metastases which were progressive under TKI therapy.

Results

All 27 targeted tumors were completely ablated, without local recurrence during the mean follow-up period of 49 months. No major complications occurred. Two minor complications were reported (11 %). Only two patients (both in group C) died at 20 and 48 months. Two-year progression-free survival (PFS) after RFA was 29 % in group A, 75 % in group B, and 20 % in group C.

Conclusions

RFA in patients, previously treated with TKI, is feasible and safe. Our data suggest that RFA is a useful therapeutic option in patients with metastatic GIST and should be performed at the time of best clinical response with patient maintained under TKI after the procedure.
Literature
1.
Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580PubMedCrossRef
2.
Rubin BP, Singer S, Tsao C et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118–8121PubMed
3.
Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710PubMedCrossRef
4.
Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRef
5.
De Matteo R, Lewis J, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence pattern and prognostic factors for survival. Ann Surg 231:51–58CrossRef
6.
Blay JY, Bonvalot S, Casali P et al (2005) Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST consensus conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 16:566–578PubMedCrossRef
7.
Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. Lancet 364:1127–1134PubMedCrossRef
8.
Rankin C, Von Mehren M, Blanke C et al (2004) Dose effect of imatinib in patients with metastatic GIST: phase III sarcoma group study S0033. J Clin Oncol 22(Suppl 14):819
9.
Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol 21:4342–4349PubMedCrossRef
10.
Debiec-Rychter M, Dumez H, Judson I et al (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 40:689–695PubMedCrossRef
11.
Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unrespectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625PubMedCrossRef
12.
Peng ZW, Lin XJ, Zhang YJ, Liang HH, Guo RP, Shi M, Chen MS (2012) Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 262(3):1022–1033PubMedCrossRef
13.
Mussi C, Ronellenfitsch U, Jakob J et al (2010) Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 21(2):403–408PubMedCrossRef
14.
Ye YJ, Gao ZD, Poston GJ, Wang S (2009) Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST). Eur J Surg Oncol 35(8):787–792PubMedCrossRef
15.
Gravante G, Overton J, Sorge R et al (2011) Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies [review]. J Gastrointest Surg 15(2):378–387PubMedCrossRef
16.
17.
Dromain C, de Baere T, Elias D et al (2002) Hepatic tumors treated with percutaneous radiofrequency ablation: CT and MR imaging follow-up. Radiology 223:255–262PubMedCrossRef
18.
Goldberg SN, Grassi CJ, Cardella JF, Society of Interventional Radiology Technology Assessment Committee, International Working Group on Image-Guided Tumor Ablation et al (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 235:728–739PubMedCentralPubMedCrossRef
19.
Duffaud F, Ray-Coquard I, Bui B et al (2009) Time to secondary resistance after interruption of imatinib: updated results of the prospective French sarcoma group randomized phase III trial on long-term survival. J Clin Oncol 27(5 Suppl):15s (abstract 10554)
20.
Agaram NP, Besmer P, Wong G et al (2007) Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13:170–181PubMedCrossRef
21.
Rutkowski P, Nowecki Z, Nyckowski P et al (2006) Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93:304–311PubMedCrossRef
22.
Blay JY, Le Cesne A, Ray-Coquard I et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25:1107–1113PubMedCrossRef
23.
Raut CP, Posner M, Desai J et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24(15):2325–2331PubMedCrossRef
24.
Jones RL, McCall J, Adam A et al (2010) Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol 36(5):477–482PubMedCrossRef
25.
de Baere T, Deschamps F, Briggs P et al (2008) Hepatic malignancies: percutaneous radiofrequency ablation during percutaneous portal or hepatic vein occlusion. Radiology 248(3):1056–1066PubMedCrossRef
26.
Hakimé A, Hines-Peralta A, Peddi H et al (2007) Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology 244(2):464–470PubMedCrossRef
27.
Hines-Peralta A, Sukhatme V, Regan M et al (2006) Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology 240(1):82–89PubMedCrossRef
28.
Casali PG, Blay JY, ESMO guidelines working group (2010) Gastrointestinal stromal tumors ESMO clinical practice guidelines for diagnosis treatment and follow-up. Ann Oncol 21(Suppl 5):98–102CrossRef
29.
Wang D, Zhang Q, Blanke CD et al (2012) Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 19(4):1074–1080PubMedCentralPubMedCrossRef
30.
Van Glabbeke M, Verweij J, Casali PG et al (2005) Initial and late resistances to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European organisation for research and treatment of cancer-Italian sarcoma group-Australian gastrointestinal trials group study. J Clin Oncol 23:5795–5804PubMedCrossRef
31.
Gronchi A, Fiore M, Miselli F et al (2007) Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245:341–346PubMedCrossRef
32.
George S, Blay JY, Casali PG et al (2008) Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, pK and pharmacodynamic analysis. J Clin Oncol 26(Suppl):566
Metadata
Title
A Role for Adjuvant RFA in Managing Hepatic Metastases from Gastrointestinal Stromal Tumors (GIST) After Treatment with Targeted Systemic Therapy Using Kinase Inhibitors
Authors
Antoine Hakimé
Axel Le Cesne
Frederic Deschamps
Geoffroy Farouil
Sana Boudabous
Anne Aupérin
Julien Domont
Thierry Debaere
Publication date
01-02-2014
Publisher
Springer US
Published in
CardioVascular and Interventional Radiology / Issue 1/2014
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-013-0615-1

Other articles of this Issue 1/2014

CardioVascular and Interventional Radiology 1/2014 Go to the issue

Clinical Investigation

Impact of Endografting on the Thoracic Aortic Anatomy: Comparative Analysis of the Aortic Geometry before and after the Endograft Implantation

Laboratory Investigation

Assessment of Chronological Effects of Irreversible Electroporation on Hilar Bile Ducts in a Porcine Model

CIRSE Standards of Practice Guidelines

Cardiovascular and Interventional Radiological Society of Europe Guidelines on Endovascular Treatment in Aortoiliac Arterial Disease

Clinical Investigation

Chemoembolization of Hepatocellular Carcinoma with Hepasphere 30–60 μm. Safety and Efficacy Study

Case Report

High Spatial Resolution MRI of Cystic Adventitial Disease of the Iliofemoral Vein Communicating with the Hip Joint

Technical Note

A Novel Technique for Inferior Vena Cava Filter Extraction